Leading gene therapy expert Brian Kaspar joins Scientific Advisory Board
ENDSULIN is fast-tracking acceleration of our treatment as we continue [...]
Based in Madison, WI
Endsulin is developing a revolutionary genetic therapy for T1DM that with a single administration would restore the body’s own ability to produce and regulate insulin. Our goal is to deliver a patented genetic factor that will “switch on” new insulin-producing cells to confer years – and perhaps a lifetime – of freedom from injecting artificial insulin, realizing the goal that has eluded researchers since the discovery of insulin.
